NCT02932137View on ClinicalTrials.gov

Anti-infection of Low-does IL-2 in SLE

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 5, 2016

Primary Completion Date

December 16, 2016

Study Completion Date

August 30, 2017

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Interleukin-2

Patients receive low dose recombinant human Interleukin-2（HrIL-2）

Trial Locations (1)

100044

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT02932137 - Anti-infection of Low-does IL-2 in SLE | Biotech Hunter | Biotech Hunter